Position Statement on the Use of Bone Turnover Markers for Osteoporosis Treatment

So Young Park¹, Seong Hee Ahn², Jun-Il Yoo³, Youn-Jee Chung⁴, Yun Kyung Jeon⁵, Byung-Ho Yoon⁶, Ha Young Kim⁷, Seung Hun Lee⁸, Jehoon Lee⁹, Seongbin Hong²

¹Division of Endocrinology and Metabolism, Department of Internal Medicine, Kyung Hee University Hospital, Seoul; ²Division of Endocrinology and Metabolism, Department of Internal Medicine, Inha University Hospital, Inha University School of Medicine, Incheon; ³Department of Orthopaedic Surgery, Gyeongsang National University Hospital, Jinju; ⁴Department of Obstetrics and Gynecology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul; ⁵Division of Endocrinology and Metabolism, Department of Internal Medicine, Pusan National University Hospital, Busan; ⁶Department of Orthopaedic Surgery, Seoul Paik Hospital, Inje University College of Medicine, Seoul; ⁷Division of Endocrinology, Department of Internal Medicine, Wonkwang University Sanbon Hospital, Wonkwang University School of Medicine, Gunpo; ⁸Division of Endocrinology and Metabolism, Asan Medical Center, University of Ulsan College of Medicine, Seoul; ⁹Department of Laboratory Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea

Current evidences continue to support the clinical application of bone turnover markers (BTMs) in the management of postmenopausal osteoporosis. The limitations of bone mineral density measured by dual energy X-ray absorptiomet especially emphasize the beneficial roles of BTMs, such as serum C-terminal telopeptide of type I collagen and serum procollagen type I N-propeptide, as monitoring tools to assess the responses to treatment. Therefore, the proper application and assessment of BTM in clinical practice is very important. However, their use in Korea is still insufficient. Therefore, the BTM committee has set up by the Korean Society for Bone and Mineral Research have been constituted and provided a position statement which will suggest on the clinical application of BTM for the management of postmenopausal osteoporosis in Korea.

Key Words: Bone remodeling · Osteoporosis · Republic of Korea

INTRODUCTION

Osteoporosis is a major health burden and its impact is expected to rise throughout the world. Osteoporosis is defined as a disease characterized by low bone mass and deteriorated bone quality, which leads to decreased bone strength and subsequent increase in the risk of fracture.[1] Bone mass is mainly expressed by bone mineral density (BMD) and bone quality is composed of microarchitecture, bone turnover rate, mineralization, and microdamage accumulation.[2] The BMD measurement using dual energy X-ray absorptiomet (DXA) is the most commonly used tool for the diagnosis of osteoporosis.[3] Although BMD is used for the determination of treatment strategy and the evaluation of bone loss rate or treatment response, it still does not completely capture the risk of osteoporotic fracture. Moreover, serial BMD measurements as a tool for treatment response require a long in-
Bone turnover, which is the process of removal of old bones by bone resorption and followed by replacement of new bones by bone formation, is continuously occurring. The change of bone turnover rate could affect the bone quality. Bone turnover marker (BTM) is an index reflecting the rate of bone turnover and BTM can be measured with urine and blood non-invasively. Considering the limitations of BMD and the characteristic of BTMs reflecting bone quality, there has been growing interest in the potential role of BTMs in predicting fracture risk and to monitoring the treatment response in clinical practice.

There is emerging evidence on clinical use of BTMs to predict bone loss and fracture risk and to monitor the response to osteoporosis treatment. Also, the measurement of BTMs will give us a better understanding of the pathogenesis of osteoporosis. However, the value of the BTMs can be influenced by several physiological and pathological factors, and, in some cases, by multiple methodologies used for the same analyte. Among various BTMs, serum C-terminal telopeptide of type I collagen (CTX-I) and serum propeptide of type I collagen (PINP) are recently recommended as a monitoring targets for osteoporosis treatment by several osteoporosis guidelines including the International Osteoporosis Foundation (IOF), the American Association of Clinical Endocrinologists/American College of Endocrinology (AACE/ACE), and the National Osteoporosis Foundation (NOF) and Japan Osteoporosis Society.

Despite this current attention in the clinical implication of BTMs for the management of postmenopausal osteoporosis, the use of BTMs is still insufficient in Korea. Therefore, the Korean Society for Bone Mineral Research organized the BTM committee to provide recommendations on their use to clinicians in Korea.

**STANDARDIZATION OF BTMs**

1. What are available assay methods for measurement of BTMs in Korea?

   BTMs are classified as either bone formation markers or bone resorption markers.

   1) Bone formation markers

      Bone formation markers include osteocalcin, bone specific alkaline phosphatase (BSALP), carboxyterminal propeptide of type I procollagen (PICP), and PINP. BSALP and osteocalcin are released by osteoblasts and play a major role in bone mineralization. PICP and PINP are cleaved from procollagen type I during collagen synthesis. In Korea, osteocalcin and BSALP are most commonly used bone formation markers. Osteocalcin is measured by immunoradiometric assay (DIAsource Immunoassays S.A., Nivelles, Belgium) and an electrochemiluminescence assay (ECLIA; Roche Diagnostics, Mannheim, Germany). BSALP is measured by chemiluminescence assay (Beckman Coulter Inc., Sacramento, CA, USA), enzyme immunoassay (Quidel Corporation, San Diego, CA, USA), and electrophoresis assay (Helena Laboratories, Beaumont, TX, USA). Although PINP has not been widely used yet in Korea, it can be measured by the ECLIA (Roche Diagnostics) and covered by insurance in osteoporotic patients recently.

   2) Bone resorption markers

      Bone resorption markers include CTX-I, N-terminal telopeptide of collagen type I (NTX-I), free and total pyridinium (PYD), and free and total deoxyPYD.

      In Korea, CTX-I is the most commonly used as a bone resorption marker and has been mainly measured by the ECLIA using β-CrossLaps kit (Roche Diagnostics).

2. Patient sample collection procedure standardization

   1) Importance of standardized patient sample collection procedure

      The primary challenge to the adoption of many BTMs in routine practice has been the poor reproducibility within-subject and between-laboratory. For clinical utility of BTMs, the pre-analytical sources of variability, along with the underlying disease process, must be identified, minimized, and controlled through carefully standardized patient preparation and sample handling procedures.

      Because serum PINP and CTX-I have recently been recommended as a reference BTM, we focused on the proper sample collection procedures for both CTX-I and PINP in this position statement.

   2) Sample collection and processing

      Although either serum or plasma sample may be used for the measurements of CTX-I and PINP, ethylenediaminetetraacetic acid plasma has the advantage over the serum as it
has superior sample stability.[15-17] The same sample type should be used consistently when monitoring a patient. CTX-I exhibits a circadian rhythm in blood. CTX-I level peaks during the early morning hours (2-5 a.m.) and reaches a nadir between 11 a.m. and 2 p.m. The only known modulator having a major effect on this circadian pattern is food intake. Overnight fasting markedly reduced the circadian variation of CTX-I. Therefore, blood samples for CTX-I measurement must be collected following an overnight fast during the morning between 7:30 a.m. and 10:00 a.m.[18-20] Other BTMs have minimal circadian rhythm and are minimally affected by food intake. Sample processing is described previously.[11]

3) Sources of pre-analytical variability: Patient related factors

The patient related factors can be divided into controllable and uncontrollable factors (Table 1). Controllable factors include the menstrual cycle, seasonal variation, and physical activities. The optimal time to collect samples in pre-menopausal women is the early-mid-follicular phase.[21] There is a minor but detectable seasonal variation for CTX-I in older adults and those with severe vitamin D deficit.[22,23] Intensive physical training (e.g., elite soccer players) moderately increases serum CTX-I and slightly decreases PINP. Vigorous exercise should be avoided the day prior to sampling.[24] Uncontrollable factors include age, sex, pregnancy, geography, renal function, and specific diseases and medications.[14]

3. Interpretation of BTMs concentrations - The role of reference intervals

The reference intervals of BTMs are useful for interpreting the results in patients with osteoporosis. Several prospective studies have reported that the presence of increased BTMs have an additive effect on the increase risk of fracture in women.[7] The very high BTM values (>3 standard deviation above the mean of the reference values) during the initial assessment suggests other metabolic bone disease than osteoporosis. However, sufficient consensus has not been achieved for determining a cut-off point of BTMs that predicts an increased fracture risk or assesses response of treatment. It is necessary to establish reference intervals of BTMs for different geographic areas and ethnicities. Although reference intervals of PINP in Korean population were previously reported[12] median level was not suggested according to menopausal state. Median serum CTX-I level was 0.279 ng/mL (range, 0.036-0.899 ng/mL) in 321 healthy premenopausal Korean women.[25] For the other BTMs including osteocalcin and NTX-1, the only data on reference intervals are given by manufactures (Table 2).

### CLINICAL UTILITY OF BTMs

1. Can BTMs predict fractures?

Elevated levels of BTM can predict more rapid rates of bone loss and higher fracture risk.

Several BTMs were introduced as having an additive effect on fracture risk in women with a low BMD.[26] Two large population-based studies found that increased levels of serum BSALP, urinary and serum CTX-I are significantly associated with an increased risk of osteoporotic fracture (hip and vertebra) with a relative risk of 2.3 to 4.8.[5,27] The predictive value of BTMs for the risk of fracture was slightly weakened, but persisted after adjustment for BMD. Additionally, the patients with both increased bone resorption markers and decreased bone formation makers were at higher risk of fracture than the patient with either one of 2 predictors.[7,27-29] These studies suggested that the index of BTMs provides the information on the risk of fracture independently of BMD, therefore, the risk of fracture

#### Table 1. Factors determining pre-analytical variability of bone turnover markers

| Uncontrolled factors | Controlled factors |
|----------------------|--------------------|
| · Age                | · Circadian rhythm |
| · Menopausal status  | · Fasting status   |
| · Gender             | · Exercise         |
| · Fracture           | · Menstrual cycle  |
| · Pregnancy and lactation | Season      |
| · Bed rest/Immobility| · Lifestyle factors (smoking, alcohol, diet) |
| · Geography and ethnicity |                |
| · Day to day variation|                  |
| · Drugs (corticosteroids, anticonvulsants, heparin, GnRH agonists, oral contraceptives) |                |
| · Diseases (thyrotoxicosis, diabetes, renal impairment, liver disease) |                |

GnRH, gonadotropin-releasing hormone.
can be assessed and supplemented with BTMs if DXA is not available.[28] Nonetheless, uncertainties over their clinical use still remain, and the routine use of BTMs to assess the fracture risk is not recommended. Despite with the association between BTMs and the risk of fracture, the previous studies have shown inconsistent findings due to their large variability.[30,31] The difference in the predictive value of the various BTMs were noted in many studies and the reasons for this discrepancy are not clear. Another critical flaw is that a common approach to statistically analyze the results of BTMs in the prediction of osteoporotic fracture is odds ratios of fractures per standard deviation of increase in BTMs (e.g., the risk of fracture in patients with higher values is compared with that with lower values).[28] The use of odds ratios is not ideal for clinical decision-making in predicting fractures, so it is not easy to apply the results to the general population.[32]

Therefore, the measurement of absolute risks, such as 10-year probabilities, should be evaluated in a further study with large population. Another possible avenue remains the development of international reference standards and standardization of their measurement that may help minimize or eliminate old problems.[33,34]

2. Can BTM monitor therapeutic efficacy?

BTMs can reflect the therapeutic responses to anti-osteoporosis therapies earlier than BMD

1) Anti-resorptive drugs

Inhibition of bone resorption by anti-resorptive drugs results in a decrease in bone resorption markers followed by a plateau. Changes in BTMs during anti-resorptive therapy depend on the mechanism of action of the drug, degree of inhibition of bone resorption, and the route of administration. This inhibition of bone resorption secondarily causes a decrease in bone formation markers, due to physiologic mechanisms linking osteoclast and osteoblast activity.

---

**Table 2.** The reference intervals and median value of available bone turnover markers in Korea

| Bone turnover marker | Sample | Assay method | Reference interval | Median |
|----------------------|--------|--------------|--------------------|--------|
| **Bone formation markers** |
| BSALP[^1]            | Serum  | CLIA         | Men: ≤20.1 μg/L     |        |
|                      |        |              | Women: premenopausal ≤14.3 μg/L |        |
|                      | Serum  | EIA          | Men: ≥25 years 15.0-41.3 U/L |        |
|                      |        |              | Women: 25-44 years 11.6-29.6 U/L |        |
| Osteocalcin[^2]      | Serum  | RIA          | Men: 21-30 years 6.0-20.0 ng/mL |        |
|                      |        |              | Women: 21-30 years 4.0-20.0 ng/mL |        |
|                      | Serum  | IRMA         | Men: 31-40 years 10.7-34.1 ng/mL |        |
|                      |        |              | Women: 31-40 years 7.7-31.9 ng/mL |        |
|                      | Serum  | ECLI A       | Men: 30-50 years 14-42 ng/mL |        |
|                      |        |              | Women: premenopausal 11-43 ng/mL |        |
| PINP                 | Serum  | ECLI A       | Men: 30-39 years 26.1-79.8 μg/L[^4] | 45.0 (37.9-54.2) |
|                      |        |              | Women: 30-39 years 18.7-83.2 μg/L | 40.0 (31.4-50.9) |

**Bone resorption markers**

| Bone turnover marker | Sample, plasma | Assay method | Reference interval | Median |
|----------------------|----------------|--------------|--------------------|--------|
| CTX-I                | Serum, plasma  | ECLI A       | Men: 30-50 years <0.584 ng/mL[^4] | 0.279 ng/mL |
|                      |                |              | Women: premenopausal 0.036-0.899 ng/mL |        |
| NTX-I[^4]            | Serum          | ELISA        | Men: 5.4-24.2 nm BCE |        |
|                      |                |              | Women: 6.2-19.0 nm BCE |        |
|                      | Urine          | EIA          | Men: 3.0-63.0 nmol BCE/mmol Cr |        |
|                      |                |              | Women: 5.0-65.0 nmol BCE/mmol Cr |        |
|                      | Urine          | CLIA         | Men: 21-83 nmol BCE/mmol Cr |        |
|                      |                |              | Women: premenopausal 17-94 nmol BCE/mmol |        |
| DPD[^4]              | Urine          | EIA, CLEIA   | Men: 2.3-5.4 nmol BCE/mmol Cr |        |
|                      |                |              | Women: 3.0-7.4 nmol BCE/mmol Cr |        |

[^1]: Described in kit manufacturer’s package insert or manufacturer’s in-house data.
[^2]: Bone specific alkaline phosphatase; PINP, propeptide of type I collagen; CTX-I, C-terminal telopeptide of type I collagen; NTX-I, N-terminal telopeptide of collagen type I; DPD, deoxypyridinoline; CLIA, chemiluminescence assay; EIA, enzyme immunoassay; RIA, radioimmunoassay; IRMA, immunoradiometric assay; ECLIA, electrochemiluminescence assay; ELISA, enzyme-linked immunosorbent assay; CLEIA, chemiluminescence enzyme immunoassay.
(1) Bisphosphonate (BP)

BPs are the most commonly used drugs for treatment of osteoporosis. Bone resorption markers are maximally suppressed after 8 weeks of treatment and bone formation markers are maximally suppressed after 26 weeks of treatment. The oral BPs, such as alendronate, ibandronate, and risedronate, have been compared in the TRIO study to evaluate the clinical utility of BTMs to assess treatment response. Alendronate and ibandronate decreased BTM (CTX-I, NTX-1) more than risedronate. In this study, more than 80% of patients responded to treatment as defined by a decrease more than the least significant change (LSC) for CTX-I (56%) and PINP (38%) after 3 months of treatment. Response can also be defined as a reduction to a level below the median found in healthy young women.[35] BPs administrated intravenously inhibit bone resorption and decrease levels of bone resorption markers faster than BPs administrated orally. Zoledronic acid is given by annual intravenous infusion, thus avoiding concerns about poor absorption. It results in a reduction in CTX-I by 2 weeks and when it is given for 6 years as in the Horizon Study, the suppression of CTX-I and PINP is maintained.[36]

(2) Denosumab

Denosumab, a fully human monoclonal antibody to receptor activator of nuclear factor-κB ligand, is administrated subcutaneously inhibited bone resorption 12 hr after administration.[13] Bone resorption markers (such as CTX-I) decrease within 24 hr of treatment. Denosumab results in a greater inhibition of bone resorption than zoledronic acid.[37] PINP decreases over several months to a lesser extent than the bone resorption markers and remains suppressed with continued dosing for up to 10 years.[38] Once the drug is stopped, the BTM overshoot so that their levels are increased compared to baseline. These elevation of BTMs results are associated with accelerated bone loss, and there are recent reports of multiple vertebral fractures associated with this high BTM.[39]

(3) Selective estrogen receptor modulator (SERM)

SERM such as raloxifene have a weaker effect on the change of bone turnover than BPs and denosumab. In 60% to 65% of women with osteopenia, a significant response could be demonstrated using the LSC approach with CTX-I or PINP.[40]

2) Anabolic drugs

The linkage between osteoclasts and osteoblasts can also function in the opposite direction, with anabolic drugs compared to anti-resorptive drugs.

(1) Recombinant human parathyroid hormone (PTH) 1-34 (teriparatide)

Teriparatide is typically characterized as an anabolic agent, but results in increases in both bone formation and resorption markers.[41,42] Bone formation markers increase within a few days of starting treatment,[42] peaking by 3 months. PINP has been proven to be the most responsive BTM to this treatment.

For monitoring of early response to teriparatide therapy, PINP is measured prior to the initiation of teriparatide, and then after 1 to 3 months of therapy. Because patients who were pre-treated with alendronate then switched to teriparatide showed PINP response rates of 79% at 1 month and 97% at 3 months, follow up assessment of PINP at 3 months may be more helpful than earlier assessments in this group of patients.[43]

The increase in serum PINP concentration by \( > 10 \text{ pg/mL} \) may be predictive of a greater increase in BMD.[43]

(2) Abaloparatide

Abaloparatide, recombinant human PTH related peptide (1-34), is a newly licensed anabolic therapy for osteoporosis.[44] It works through the PTH receptor as does teriparatide. This drug stimulates rapid bone formation and resorption and works in a dose dependent manner in women with postmenopausal osteoporosis, but less than teriparatide, leading to a greater increase in BMD compared with teriparatide.[45] The clinical utility of BTMs for monitoring abaloparatide therapy has not yet been fully reported.

(3) Romosozumab

Romosozumab, anti-sclerostin monoclonal antibody, also works in a dose-dependent manner and increases bone formation markers. But, unlike teriparatide, there is an early but transient increase in PINP level and a decrease in serum CTX-I.[46] PINP level begin to increase from 1 week after drug administration and reaches a peak in 1 month, then slowly return to pretreatment values within 6 months. CTX-I initially decreased and remained below the baseline value at 12 month.[46] These BTM changes are associated with a rapid increase in BMD.
3. Can BTM monitor compliance?
In postmenopausal women receiving a treatment, BTMs can be used to monitor the individual compliance. Monitoring of BTM at an individual level may improve the compliance of patients on anti-osteoporotic treatment.[47] The IOF has proposed that a BTM such as PINP or CTX-I measured within 3 months of starting therapy would help to identify those with poor adherence which occur commonly with osteoporosis therapy, especially oral BPs.[48] The absence of change in the BTMs concentration during anti-osteoporotic therapy might reflect poor compliance (e.g., BP not taken at all, or not taken in the fasting state, or taken with milk), poor adherence, inappropriate technique of teriparatide injection, a medical problem (e.g., recent vertebral fracture), secondary osteoporosis, or real absence of response.

According to recently published Consensus Statement in Asia-Pacific region,[49] in patients who are receiving anti-resorptive therapies, serum CTX-I and/or PINP can be used to monitor compliance and drug response with measurements at baseline, 3, 6, and 12 months after starting treatment. In patients who are receiving anabolic therapies, serum PINP can be used to monitor compliance and drug response, with measurements at baseline, 1 to 3, 6, and 12 months after starting treatment.

However, further studies are necessary to define an adequate response through the change in BTM concentration that is associated with a greater reduction in fracture incidence. The reference range of BTMs concentration for the adequate response could be helpful when used as target for anti-osteoporotic treatment.

4. Can BTMs be useful for drug holiday?
Monitoring BTMs during drug holiday can be helpful to decide to resume treatment, but the evidence was insufficient yet.

BPs are considered as a first-line treatment for osteoporosis. It is effective in reduction of fracture risk over 3 to 5 years of treatment. However, long-term use of BPs is associated with the rare but serious adverse effects such as osteonecrosis of the jaw (ONJ) and atypical femoral fractures (AFF). Therefore, the concept of a ‘drug holiday’ from BPs has emerged as being potentially beneficial in avoiding these adverse effects. The effect of BP such as anti-resorption and fracture prevention persist for a long period after cessation of drugs because of long-term deposition of BPs in bones. However, despite BP has long skeletal retention time, fracture risk will increase after discontinuation of it. Therefore, continuous monitoring during drug holiday will be needed for the assessment of fracture risk and to restart treatment if needed. There are limited clinical practice guidelines on BTM monitoring during drug holiday. There are few studies about an assessment of fracture risk using BTMs during drug holiday. A recent retrospective study showed that those in newly developed fracture group during drug holiday was older and had lower BMD than non-fracture group. Other factors associated with fracture such as BTMs, vitamin D level, body mass index, and PTH were not significantly different between 2 groups.[50] Another study presented that BMD by DXA, BTMs (CTX-I, PINP), and fracture-risk assessment tool score may help to guide when to resume treatment during drug holiday.[51] Some researchers suggested that empirical approaches such as monitoring BMD and BTMs are necessary during drug holiday.[52] Several meta-analyses presented that increased bone turnover is a significant determinant of fracture susceptibility.[53-55] In one guideline, they suggested that the increase in bone resorption markers compared to the levels before treatment might be a signal to stop the “holiday”.[56] During drug holiday, a significant decrease in BMD or a significant increase in BTMs suggests that the residual effect of BP therapy may be diminishing and that it may be time to resume active therapy.[52,57,58] Roberts and colleagues[51] recommended that if BTMs rise over 30% after drug holiday, treatment should be resumed.

5. Could BTMs predict side effects such as ONJ and AFF?
Although there is still controversy, BTMs can be used carefully as a predictor of long-term side effects of BPs such as ONJ and AFF.

Prolonged BP therapy has been related with rare adverse events such as ONJ and AFF. ONJ is a rare oral disease in which the jaw bone’s healing power is impaired because of use of BP or other antiresorptive agents. Patients may be considered to have ONJ if they had current or previous treatment with antiresorptive or antiangiogenic agents and as if there is exposed bone in the jaw that has persisted for more than 8 weeks but without history of radiation therapy or obvious metastatic disease.[59] A number of case reports have suggested that long-term treatment...
with BPs may be related to the occurrence of fractures of the femur below the lesser trochanter, which was regarded as an atypical based on their unusual site and radiographic appearance in patients with osteoporosis.[60] These rare but serious side effects were supposed to be related to the severely suppression of bone turnover. Therefore, several biochemical markers have been used as effective evaluation methods during the bone-remodeling period. In one cross-sectional study, 4 BTMs including serum CTX-I, osteocalcin, PTH, and BSALP were compared between medication-related ONJ patients and control groups. Serum CTX-I, osteocalcin, and BSALP levels were lower and serum PTH level was higher in ONJ patients than in control groups.[59] Another study showed that high CTX-I level was associated with a low risk of ONJ in patients who was treated with BPs and had a tooth extraction.[61] BSALP level over 10 μg/L denoted faster healing and indicated a better prognosis in ONJ patients.[62] Some dentists have suggested CTX-I measurement for the prediction of ONJ. If patients’ CTX-I level is lower than 0.100 to 0.150 ng/mL, the risk of ONJ is high, therefore, drug holiday or having surgery after recovery of CTX-I level could be recommended.[63,64] One prospective cross-sectional study suggested that the levels of BTMs including PINP, tartrate-resistant acid phosphatase 5b (TRACP-5b) and undercarboxylated osteocalcin were significantly lower in patients with AFF than in patients with typical osteoporotic femoral fracture. They suggested that severe suppression of bone turnover was associated with the pathogenesis of AFF.[65] Systematic review of case report and case series on AFF presented that bone formation marker was decreased in 14%, normal in 79%, and increased in 7.0% in AFF patients. And bone resorption marker was decreased 18.2%, normal 69.7%, and increased 12.1% in AFF patients.[60]

6. How should BTM be used in patient with chronic kidney disease (CKD)?

The various serum and urine BTMs are affected by renal dysfunction. The measurement of BSALP and PTH is recommended as a BTM in patients with CKD. Because of urinary and some serum BTMs are excreted into urine by kidney, the serum level of those are affected by renal dysfunction. BSALP, intact PINP, and TRACP-5b are not affected by renal impairment.

1) BSALP

Its serum concentration seems to be independent of glomerular filtration rate. Combination of a low PTH (<150 pg/mL) and a low BSALP (<27 IU/L) improved the specificity of diagnosing adynamic bone disease in 103 dialysis patients with bone biopsy. In the newer automated Ostase BSALP assay, the cut-off <20 IU/L is used.[66]

2) Osteocalcin

Since osteocalcin is cleared by kidney, its use in CKD patients is limited. The combination of osteocalcin (<41 ng/L) and BSALP (<23 U/L) improved the positive predictive value for diagnosing adynamic bone disease to 77% in a CKD-5 cohort.[66]

3) PINP

PINP is present in 2 major forms, an intact trimeric form and a monomeric one. Some assays recognize both forms (‘Total PINP’; Roche Elecsys, Mannheim, Germany) while other assays recognize the trimeric form only (‘Intact PINP’; Orion Diagnostica and IDS iSYS). The proportion of the monomeric form is elevated in patients with CKD, whereas the apparent concentration of intact PINP is unaffected by glomerular filtration rate in kidney disease patients.[67] PINP monomers are not cleared by conventional dialysis sessions and the LSC is of 32% for the intact assay.[68]

4) CTX-I

CTX-I is renally excreted and accumulates in CKD patients. CTX-I is cleared by dialysis and therefore pre-dialysis sampling is required for longitudinal monitoring.[66]

5) TRACP-5b

TRACP-5b is an enzyme released by osteoclasts to breakdown bone matrix. High serum levels of TRACP-5b therefore reflect increased osteoclastic activity and resorption. Levels of TRACP-5b correlate with PTH and ALP and are unaffected by renal function. However, its use is limited by availability of automated assays.[66]

6) The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines for CKD-mineral and bone disorder (CKD-MBD)

The KDIGO guidelines recommended that the bone derived markers of collagen synthesis and breakdown, includ-
ing CTX-I, should not be routinely measured in patients with CKD stages 3 to 5D.[69] The primary rationale for this recommendation was that the levels of such markers did not appear to be more effective at predicting clinical outcomes or bone histology than serum PTH or BASLP.[70] However, they suggest that measurements of serum PTH or BASLP can be used to evaluate bone disease because markedly high or low values predict underlying bone turnover in patients with CKD G3a-G5D.[69] They also recommend the interval of monitoring serum calcium, phosphate, and PTH on the presence and magnitude of abnormalities, based on rate of progression of CKD (Table 3).[69]

### Table 3. The interval of monitoring serum calcium, phosphate, and parathyroid hormone based on rate of progression of chronic kidney disease

| CKD stage       | Monitoring of parameters                                                                 |
|-----------------|------------------------------------------------------------------------------------------|
| CKD G3a-G3b     | Check serum calcium and phosphate, every 6-12 months; and for PTH, based on baseline level and CKD progression |
| CKD G4          | Check serum calcium and phosphate, every 3-6 months; and check PTH, every 6-12 months     |
| CKD G5 (including G5D) | Check serum calcium and phosphate, every 1-3 months; and check PTH, every 3-6 months    |
| CKD G4-G5D      | Check alkaline phosphatase activity, every 12 months, or more frequently in the presence of elevated PTH |

CKD, chronic kidney disease; PTH, parathyroid hormone; CKD G5D, chronic kidney disease stage 5 receiving dialysis.

### CONCLUSION

The appropriate use of BTMs in treatment of osteoporosis could be helpful to predict fracture risk and monitor treatment response and patient compliance. But, BTMs have not been used widely in clinical practice due to their poor within-subject and between-lab reproducibility. Researchers are constantly trying to automate and standardize the measurement of bone markers to minimize variability of BTMs. In addition, insurance coverage for BTMs have recently been possible in Korea. Thus, BTMs could be used easily as a dynamic index reflecting bone quality, complementary to BMD. More studies about the efficacy of BTMs are needed in the future.

---

**Fig. 1.** The algorithm of bone turnover marker use in osteoporosis treatment. PINP, propeptide of type I collagen; BSALP, bone specific alkaline phosphatase; CTX-1, C-terminal telopeptide of type I collagen; NTX-1, N-terminal telopeptide of collagen type I; DPD, deoxypyridinoline; PYD, pyridinoline; BP, bisphosphonate; SERM, selective estrogen receptor modulator; LSC, least significant changes.
SUMMARIES OF CONSENSUS STATEMENT (Fig. 1)

- Consider using BTMs in the initial evaluation and follow-up of patients with osteoporosis.
- Elevated levels of BTMs can predict more rapid rates of bone loss and higher fracture risk.
- BTMs can reflect the therapeutic responses to anti-osteoporosis therapies earlier than BMD and help in selecting osteoporosis treatment and in assessing response to therapies.
- CTX-I and/or PINP can be used to evaluate patient adherence and response to anti-resorptive drugs with measurement at baseline, 3 to 6 months after starting treatment.
- PINP can be used to evaluate patient adherence and responses to anabolic agents with measurement at baseline, 1 to 3 months after starting treatment.
- For patients taking anti-resorptive agents, target range for successful treatment is to have levels of BTMs in the reference range for premenopausal women. Also, relative change of BTMs from baselines above LSC can be also used.
- Monitoring BTMs during drug holiday can be helpful to decide to resume treatment, but the evidence was insufficient yet.
- Although there is still controversy, BTMs can be used carefully as a predictor of long-term side effects of BPs such as ONJ and AFF.
- The various serum and urine BTMs are affected by renal dysfunction. The measurement of BASLP and PTH is recommended as a BTM in patients with CKD.

DECLARATIONS

Ethics approval and consent to participate
Not applicable.

Conflict of interest
No potential conflict of interest relevant to this article was reported.

ORCID
So Young Park https://orcid.org/0000-0002-4820-9415
Yun Kyung Jeon https://orcid.org/0000-0002-4319-5181

REFERENCES

1. Peck WA, Burckhardt P, Christiansen C, et al. Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 1993;94:646-50.
2. Weinstein RS. True strength. J Bone Miner Res 2000;15:621-5.
3. Blake GM, Fogelman I. Role of dual-energy X-ray absorptiometry in the diagnosis and treatment of osteoporosis. J Clin Densitom 2007;10:102-10.
4. Feng X, McDonald JM. Disorders of bone remodeling. Annu Rev Pathol 2011;6:121-45.
5. Gamero P, Hausherr E, Chapuy MC, et al. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res 1996;11:1531-8.
6. Gamero P, Somay-Rendu E, Claustrat B, et al. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OLEVLY study. J Bone Miner Res 2000;15:1526-36.
7. Ross PD, Kress BC, Parson RE, et al. Serum bone alkaline phosphatase and calcaneus bone density predict fractures: a prospective study. Osteoporos Int 2000;11:76-82.
8. Cosman F, de Beur SJ, LeBoff MS, et al. Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int 2014;25:2359-81.
9. Orimo H, Nakamura T, Hosoi T, et al. Japanese 2011 guidelines for prevention and treatment of osteoporosis—executive summary. Arch Osteoporos 2012;7:3-20.
10. Vasikaran S, Eastell R, Bruyere O, et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int 2011;22:391-420.
11. Park SY, Ahn SH, Yoo JI, et al. Clinical application of bone turnover markers in osteoporosis in Korea. J Bone Metab 2019;26:19-24.
12. Nishizawa Y, Ohta H, Miura M, et al. Guidelines for the use of bone metabolic markers in the diagnosis and treatment of osteoporosis (2012 edition). J Bone Miner Metab 2013;31:1-15.
13. Szulc P. The role of bone turnover markers in monitoring treatment in postmenopausal osteoporosis. Clin Biochem 2012;45:907-19.
14. Szulc P, Naylor K, Hoyle NR, et al. Use of CTX-I and PINP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability. Osteoporos Int 2017;28:2541-56.
15. Christgau S, Rosenquist C, Alexandersen P, et al. Clinical evaluation of the Serum CrossLaps One Step ELISA, a new assay measuring the serum concentration of bone-derived degradation products of type I collagen C-telopeptides. Clin Chem 1998;44:2290-300.
16. Garnero P, Borel O, Delmas PD. Evaluation of a fully automated serum assay for C-terminal cross-linking telopeptide of type I collagen in osteoporosis. Clin Chem 2001;47:694-702.
17. Morovat A, Catchpole A, Meurisse A, et al. IDS iSYS automated intact procollagen-1-N-terminus pro-peptide assay: method evaluation and reference intervals in adults and children. Clin Chem Lab Med 2013;51:2009-18.
18. Qvist P, Christgau S, Pedersen BJ, et al. Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting. Bone 2002;31:57-61.
19. Redmond J, Fulford AJ, Jarjou L, et al. Diurnal rhythms of bone turnover markers in three ethnic groups. J Clin Endocrinol Metab 2016;101:3222-30.
20. Clowes JA, Hannon RA, Yap TS, et al. Effect of feeding on bone turnover markers and its impact on biological variability of measurements. Bone 2002;30:886-90.
21. Gass ML, Kagan R, Kohles JD, et al. Bone turnover marker profile in relation to the menstrual cycle of premenopausal healthy women. Menopause 2008;15:667-75.
22. Bhattoa HP, Nagy E, More C, et al. Prevalence and seasonal variation of hypovitaminosis D and its relationship to bone metabolism in healthy Hungarian men over 50 years of age: the HunMen Study. Osteoporos Int 2013;24:179-86.
23. Pasco JA, Henry MJ, Lunan CB, et al. Seasonal periodicity of serum vitamin D and parathyroid hormone, bone resorption, and fractures: the Geelong Osteoporosis Study. J Bone Miner Res 2004;19:752-8.
24. Weiler R, Keen R, Wolman R. Changes in bone turnover markers during the close season in elite football (soccer) players. J Sci Med Sport 2012;15:255-8.
25. Bae SJ, Kim BJ, Lim KH, et al. Efficacy of intravenously administered ibandronate in postmenopausal Korean women with insufficient response to orally administered bisphosphonates. J Bone Miner Metab 2012;30:588-95.
26. Johnell O, Odén A, De Laet C, et al. Biochemical indices of bone turnover and the assessment of fracture probability. Osteoporos Int 2002;13:523-6.
27. Vergnaud P, Garnero P, Meunier PJ, et al. Undercarboxylated osteocalcin measured with a specific immunoassay predicts hip fracture in elderly women: the EPIDOS Study. J Clin Endocrinol Metab 1997;82:719-24.
28. Garnero P, Cloos P, Sornay-Rendu E, et al. Type I collagen racemization and isomerization and the risk of fracture in postmenopausal women: the OFELY prospective study. J Bone Miner Res 2002;17:826-33.
29. Gerdhem P, Ivaska KK, Alatalo SL, et al. Biochemical markers of bone metabolism and prediction of fracture in elderly women. J Bone Miner Res 2004;19:386-93.
30. Marques EA, Gudnason V, Lang T, et al. Association of bone turnover markers with volumetric bone loss, periosteal apposition, and fracture risk in older men and women: the AGES-Reykjavik longitudinal study. Osteoporos Int 2016;27:3485-94.
31. Melton LJ 3rd, Crowson CS, O’Fallon WM, et al. Relative contributions of bone density, bone turnover, and clinical risk factors to long-term fracture prediction. J Bone Miner Res 2003;18:312-8.
32. Leiper JM, Paterson KR, Lunan CB, et al. A comparison of biosynthetic human insulin with porcine insulin in the blood glucose control of diabetic pregnancy. Diabet Med 1986;3:49-51.
33. Ulivieri FM, Piodi LP, Grossi E, et al. The role of carboxy-terminal cross-linking telopeptide of type I collagen, dual x-ray absorptiometry bone strain and Romberg test in a new osteoporotic fracture risk evaluation: A proposal from an observational study. PLoS One 2018;13:e0190477.
34. Vasikaran S. Assessment of bone turnover in osteoporosis: harmonization of the total testing process. Clin Chem Lab Med 2018;56:1603-7.
35. Naylor KE, Jacques RM, Paggiosi M, et al. Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study. Osteoporos Int 2016;27:21-31.
36. Black DM, Reid IR, Cauley JA, et al. The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 2015;30:934-44.
37. Miller PD, Pannacciulli N, Brown JP, et al. Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates. J Clin Endocrinol Metab 2016;101:3163-70.
38. Bone HG, Wagman RB, Brandi ML, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 2017;5:513-23.
39. Lamy O, Gonzalez-Rodriguez E, Stoll D, et al. Severe rebound-associated vertebral fractures after denosumab discontinuation: 9 clinical cases report. J Clin Endocrinol Metab 2017;102:354-8.
40. Naylor KE, Jacques RM, Peel NF, et al. Response of bone turnover markers to raloxifene treatment in postmenopausal women with osteopenia. Osteoporos Int 2016;27:2585-92.
41. Finkelstein JS, Leder BZ, Burnett SM, et al. Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men. J Clin Endocrinol Metab 2006;91:2882-7.
42. Glover SJ, Eastell R, McCloskey EV, et al. Rapid and robust response of biochemical markers of bone formation to teriparatide therapy. Bone 2009;45:1053-8.
43. Eastell R, Krege JH, Chen P, et al. Development of an algorithm for using PINP to monitor treatment of patients with teriparatide. Curr Med Res Opin 2006;22:61-6.
44. Shirley M. Abaloparatide: First global approval. Drugs 2017;77:1363-8.
45. Miller PD, Hattersley G, Riis BJ, et al. Effect of Abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: A randomized clinical trial. JAMA 2016;316:722-33.
46. McClung MR, Grauer A, Boonen S, et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 2014;370:412-20.
47. Delmas PD, Vrijens B, Eastell R, et al. Effect of monitoring bone turnover markers on persistence with risendronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 2007;92:1296-304.
48. Diez-Perez A, Naylor KE, Abrahamsen B, et al. International osteoporosis foundation and European calcified tissue society working group. Recommendations for the screening of adherence to oral bisphosphonates. Osteoporos Int 2017;28:767-74.
49. Sun V, Raz DJ, Erhunmwunsee L, et al. Improving family caregiver and patient outcomes in lung cancer surgery: Study protocol for a randomized trial of the multimedia self-management (MSM) intervention. Contemp Clin Trials 2019;83:88-96.
50. Bindon B, Adams W, Balasubramanian N, et al. Osteorotic fractures during bisphosphonate drug holiday. Endocr Pract 2018;24:163-9.
51. Roberts J, Castro C, Moore AE, et al. Changes in bone mineral density and bone turnover in patients on ‘drug holiday’ following bisphosphonate therapy: real-life clinical setting. Clin Endocrinol (Oxf) 2016;84:509-15.
52. McClung M, Harris ST, Miller PD, et al. Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med 2013;126:13-20.
53. Bonnick SL, Shulman L. Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both? Am J Med 2006;119:S25-31.
54. Wasnich RD, Miller PD. Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 2000;85:231-6.
55. Cummings SR, Karpf DB, Harris F, et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 2002;112:281-9.
56. Camacho PM, Petak SM, Binkley N, et al. American association of clinical endocrinologists and American college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis - 2016. Endocr Pract 2016;22:1-42.
57. Lee SH, Gong HS, Kim TH, et al. Position statement: Drug holiday in osteoporosis treatment with bisphosphonates in South Korea. J Bone Metab 2015;22:167-74.
58. Anagnostis P, Stevenson JC. Bisphosphonate drug holidays-when, why and for how long? Climacteric 2015;18 Suppl 2:32-8.
59. Peisker A, Raschke GF, Fahmy MD, et al. Cross-sectional study of four serological bone turnover markers for the risk assessment of medication-related osteonecrosis of the jaw. J Craniofac Surg 2018;29:e137-e40.
60. Giusti A, Hamdy NA, Papapoulos SE. Atypical fractures of the femur and bisphosphonate therapy: A systematic review of case/case series studies. Bone 2010;47:169-80.
61. Friedlander AH, Chang TL, Hazboun RC, et al. High C-terminal cross-linking telopeptide levels are associated with a minimal risk of osteonecrosis of the jaws in patients tak-
ing oral bisphosphonates and having exodontia. J Oral Maxillofac Surg 2015;73:1735-40.
62. Lee JJ, Cheng SJ, Wang JJ, et al. Factors predicting the prognosis of oral alendronate-related osteonecrosis of the jaws: a 4-year cohort study. Head Neck 2013;35:1787-95.
63. Lee CY, Suzuki JB. CTX biochemical marker of bone metabolism. Is it a reliable predictor of bisphosphonate-associated osteonecrosis of the jaws after surgery? Part II: a prospective clinical study. Implant Dent 2010;19:29-38.
64. Lee CY, Suzuki JB. CTX biochemical marker of bone metabolism. Is it a reliable predictor of bisphosphonate-associated osteonecrosis of the jaws after surgery? Part I: biological concepts with a review of the literature. Implant Dent 2009;18:492-500.
65. Iizuka Y, Iizuka H, Kaneko T, et al. Bone turnover markers and the factors associated with atypical femur fractures among Japanese patients. Injury 2016;47:2484-9.
66. Chiang C. The use of bone turnover markers in chronic kidney disease-mineral and bone disorders. Nephrology (Carlton) 2017;22 Suppl 2:11-3.
67. Ueda M, Inaba M, Okuno S, et al. Clinical usefulness of the serum N-terminal propeptide of type I collagen as a marker of bone formation in hemodialysis patients. Am J Kidney Dis 2002;40:802-9.
68. Cavalier E, Delanaye P, Moranne O. Variability of new bone mineral metabolism markers in patients treated with maintenance hemodialysis: implications for clinical decision making. Am J Kidney Dis 2013;61:847-8.
69. Isakova T, Nickolas TL, Denburg M, et al. KDOQI US commentary on the 2017 KDIGO clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Am J Kidney Dis 2017;70:737-51.
70. Delanaye P, Souberbielle JC, Lafage-Proust MH, et al. Can we use circulating biomarkers to monitor bone turnover in CKD haemodialysis patients? Hypotheses and facts. Nephrol Dial Transplant 2014;29:997-1004.